Canaccord analyst Whitney Ijem raised the firm’s price target on Palvella Therapeutics (PVLA) to $204 from $148 and keeps a Buy rating on the shares. The firm said the initial Ph2 data for QTORIN rapamycin’s 2nd indication, cutaneous venous malformation (cVM), was a win. The company had been looking for at least a 30% response rate so the 73% of patients who improved on the cVM-IGA at Week 12 far surpasses expectations, and means it won’t be hard/ expensive to design an efficient pivotal study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Buy Rating Affirmed for Palvella Therapeutics Following Promising Phase 2 TOIVA Trial Results
- Palvella Therapeutics price target raised to $174 from $110 at Chardan
- Palvella Therapeutics price target raised to $190 from $105 at Truist
- Promising Clinical Data and Market Potential Drive Buy Rating for Palvella Therapeutics’ QTORIN Rapamycin
- Palvella Therapeutics price target raised to $200 from $190 at H.C. Wainwright